- Home
- COEP vs ONVO Comparison
COEP vs ONVO Comparison
Compare COEP & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ONVO
- Stock Information
- Founded
- COEP 2017
- ONVO 2007
- Country
- COEP United States
- ONVO United States
- Employees
- COEP N/A
- ONVO N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COEP Health Care
- ONVO Health Care
- Exchange
- COEP Nasdaq
- ONVO Nasdaq
- Market Cap
- COEP 8.1M
- ONVO 7.2M
- IPO Year
- COEP N/A
- ONVO N/A
- Fundamental
- Price
- COEP $0.21
- ONVO $0.34
- Analyst Decision
- COEP
- ONVO
- Analyst Count
- COEP 0
- ONVO 0
- Target Price
- COEP N/A
- ONVO N/A
- AVG Volume (30 Days)
- COEP 282.8K
- ONVO 89.1K
- Earning Date
- COEP 11-13-2024
- ONVO 11-26-2024
- Dividend Yield
- COEP N/A
- ONVO N/A
- EPS Growth
- COEP N/A
- ONVO N/A
- EPS
- COEP N/A
- ONVO N/A
- Revenue
- COEP N/A
- ONVO $103,000.00
- Revenue This Year
- COEP N/A
- ONVO $59.08
- Revenue Next Year
- COEP N/A
- ONVO $18.24
- P/E Ratio
- COEP N/A
- ONVO N/A
- Revenue Growth
- COEP N/A
- ONVO N/A
- 52 Week Low
- COEP $0.15
- ONVO $0.35
- 52 Week High
- COEP $1.33
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- COEP 50.31
- ONVO 31.18
- Support Level
- COEP $0.19
- ONVO $0.39
- Resistance Level
- COEP $0.22
- ONVO $0.46
- Average True Range (ATR)
- COEP 0.02
- ONVO 0.04
- MACD
- COEP -0.00
- ONVO -0.01
- Stochastic Oscillator
- COEP 46.15
- ONVO 1.54
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.